ABVX — Abivax SA Income Statement
0.000.00%
Last trade - 00:00- $437.69m
- $374.53m
Annual income statement for Abivax SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | FAS | FAS | FAS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | -0.001 | — | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 37.8 | 42.4 | 70.5 | 127 | 173 |
| Operating Profit | -37.8 | -42.4 | -70.5 | -127 | -173 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -40.1 | -45.6 | -74.3 | -148 | -176 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -37.6 | -41.4 | -69.8 | -148 | -176 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -37.6 | -41.4 | -69.8 | -148 | -176 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -37.6 | -41.4 | -69.8 | -148 | -176 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.63 | -2.47 | -2.73 | -3.43 | -2.8 |
| Dividends per Share |